Welcome to Caldera Health Limited
Caldera Health Limited, registered in Auckland, New Zealand on February 9, 2009 is developing novel diagnostic tests in the field of prostate cancer and men’s health.
Caldera’s business goals are to use molecular technologies to develop a range of diagnostic devices for detecting early stage prostate cancer, and determining the phenotype of the prostate cancer.
Caldera’s diagnostic platform is underpinned by proprietary Footprint II™ technology, which has been compiled from microarray databases from public domain prostate cancer and healthy prostate tissues. Caldera’s strategy has been to use this technology to select three layers of biomarkers for detecting early prostate cancer. These are expressed RNA and secreted proteins identified from these expressed RNA, and antibodies to secreted proteins.
Diagnostics for Prostate Cancer
The uniqueness of the Company approach is the prognosis power of the biomarkers which relate the biology of individual tumours to whether the tumour is likely to be high, intermediate or low risk to the patient’s life.
Caldera seeks to rapidly expand into international markets by out-licensing its diagnostic content to molecular diagnostic companies who have platforms to develop and market diagnostic test kits to regionally significant diagnostic service providers. Caldera seeks revenues from licence fees and royalties on test kits.
Caldera is interested to talk to diagnostic companies that might be interested to in-licence protein and expressed RNA biomarkers for integration into their technology platform(s).